Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorOaknin, A.
dc.contributor.authorIglesias, M.
dc.contributor.authorAlarcon, J. D.
dc.contributor.authorVillacampa Javierre, G.
dc.contributor.authorGaba Garcia, L.
dc.contributor.authorSantaballa, A.
dc.contributor.authorManso, L. M.
dc.contributor.authorRomero, I.
dc.contributor.authorBarretina Ginesta, M. P.
dc.contributor.authorChurruca, C.
dc.contributor.authorGarcia, Y.
dc.contributor.authorSanchez, A. B.
dc.contributor.authorMarquina, G.
dc.contributor.authorPardo, B.
dc.contributor.authorRedondo, A.
dc.contributor.authorRubio, M. J.
dc.contributor.authorGonzalez Martin, A.
dc.contributor.authoraffiliation[Oaknin, A.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Iglesias, M.] Hosp Son Llatzer, Med Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Alarcon, J. D.] Hosp Univ Son Espases, Dept Med Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Villacampa Javierre, G.] Vall dHebron Inst Oncol VHIO Cellex Ctr, Dept Stat, Barcelona, Spain
dc.contributor.authoraffiliation[Gaba Garcia, L.] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Santaballa, A.] Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Manso, L. M.] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Romero, I.] Fdn Inst Valenciano Oncol, Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Barretina Ginesta, M. P.] ICO Inst Catala Oncol Girona Hosp Univ Josep True, Dept Med Oncol, Girona, Spain
dc.contributor.authoraffiliation[Churruca, C.] Hosp Donosti, Med Oncol, Donosti, Spain
dc.contributor.authoraffiliation[Garcia, Y.] Hosp Sabadell, Med Oncol, Sabadell, Spain
dc.contributor.authoraffiliation[Sanchez, A. B.] Hosp Gen Univ Elche, Med Oncol, Elche, Spain
dc.contributor.authoraffiliation[Marquina, G.] Hosp Clin Univ San Carlos, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Pardo, B.] Hosp Duran & Reynals, Inst Catala Oncol, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Redondo, A.] Hosp Univ La Paz, Dept Oncol Med, Madrid, Spain
dc.contributor.authoraffiliation[Rubio, M. J.] Univ Hosp Reina Sofia, Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Gonzalez Martin, A.] Clin Univ Navarra, Med Oncol Dept, Madrid, Spain
dc.contributor.funderGSK/Tesaro
dc.date.accessioned2025-01-07T13:12:58Z
dc.date.available2025-01-07T13:12:58Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.1019
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420410154/pdf
dc.identifier.urihttps://hdl.handle.net/10668/25336
dc.identifier.wosID573469101168
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.page.numberS645-S645
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleRandomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía